Showing results (1471-1480 of 5,932) with videos related to
Sort By:
Pageof 594
The Prostate|September 2, 2014
Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasiaKenneth C Valkenburg, Xiuping Yu, Angelo M De Marzo, et al.The Prostate|November 26, 2013
Pirin down-regulates the EAF2/U19 protein and alleviates its growth inhibition in prostate cancer cellsZhongjie Qiao, Dan Wang, Junghyun Hahn, et al.The Prostate|August 19, 2015
Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic markerAsha Leisser, Konstatin Pruscha, Philipp Ubl, et al.The Prostate|January 1, 1989
Case-control study of prostatic cancer in Kyoto, Japan: demographic and some lifestyle risk factorsK Oishi, K Okada, O Yoshida, et al.The Prostate|March 10, 2016
Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subsetSilvia Hernández, Alba Font-Tello, Núria Juanpere, et al.The Prostate|March 28, 2013
Age-related alterations in T-lymphocytes modulate key pathways in prostate tumorigenesisAlejandra De Angulo, Robert Faris, David Cavazos, et al.The Prostate|March 28, 2013
Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressivenessRomain Mathieu, Bertrand Evrard, Gaëlle Fromont, et al.The Prostate|March 28, 2013
Exogenous SPARC suppresses proliferation and migration of prostate cancer by interacting with integrin β1Minkyoung Shin, Atsushi Mizokami, Jungim Kim, et al.The Prostate|September 2, 2014
ERG expression in prostate cancer: the prognostic paradoxMichael Taris, Jacques Irani, Pascal Blanchet, et al.The Prostate|September 2, 2014
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancerRosa Nadal, Zhe Zhang, Hibba Rahman, et al.Pageof 594